I Department of Lung Diseases, National Tuberculosis and Lung Diseases Research Institute, ul Plocka 26, 01-138, Warsaw, Poland.
Department of Radiology, National Tuberculosis and Lung Diseases Research Institute, Plocka 26, 01-138, Warsaw, Poland.
BMC Cardiovasc Disord. 2020 Aug 27;20(1):392. doi: 10.1186/s12872-020-01674-z.
Pericardial constriction is one of the complications of purulent pericarditis (PP). Most difficult to treat, which may develop both in early and in the late period of the disease, resulting in a very poor prognosis.
We present case series of 4 patients with purulent pericarditis, in whom direct intrapericardial administration of recombinant tissue plasminogen activator (r-tPA) was used. Management of PP requires a combined surgical and medical approach. The most important is complete drainage of the effusion by subxiphoid pericardiotomy connected with complementary use of broad-spectrum antibiotics. Despite the use of broad- spectrum antibiotics, in some patients a large volume of daily drainage is still present. Constrictive pericarditis as a complication of PP is observed in majority of patients. Intrapericardial administration of fibrinolytic agents, although not strongly recommended, can improve efficacy of antibiotic treatment especially in patients with loculation fluid and can prevent the development of constrictive pericarditis. r-tPA was applied at a dose of 20 mg dissolved in 100 ml of normal saline in a 100 ml syringe, administered by a large pericardial drain (Pezzer drain) installed into the pericardial cavity during pericardioscopy. The tube was closed and re-opened after 24 h. No serious complications, such as bleeding, allergy or hypotension, were noted.
We present case series of 4 patients with purulent pericarditis, in whom direct intrapericardial administration of recombinant tissue plasminogen activator (r-tPA), prevented the development of constrictive pericarditis, and increased efficacy of antibiotic treatment without any significant complications.
心包缩窄是化脓性心包炎 (PP) 的并发症之一。这种并发症最难治疗,可能发生在疾病的早期和晚期,导致预后非常差。
我们报告了 4 例化脓性心包炎患者的病例系列,其中使用了重组组织纤溶酶原激活剂 (r-tPA) 直接心包内给药。PP 的治疗需要综合手术和药物治疗。最重要的是通过剑突下心包切开术完全引流渗出液,并与广谱抗生素联合使用。尽管使用了广谱抗生素,但在某些患者中,仍存在大量每日引流。化脓性心包炎的并发症在大多数患者中观察到。尽管心包内给予纤维蛋白溶解剂不被强烈推荐,但可以提高抗生素治疗的疗效,特别是在有分隔积液的患者中,并可以预防心包缩窄的发生。r-tPA 以 20mg 的剂量溶解在 100ml 生理盐水中,通过心包镜检查时在心包腔内放置的大心包引流管 (Pezzer 引流管) 给药。关闭引流管,24 小时后再打开。未观察到严重并发症,如出血、过敏或低血压。
我们报告了 4 例化脓性心包炎患者的病例系列,其中直接心包内给予重组组织纤溶酶原激活剂 (r-tPA) 预防了心包缩窄的发生,并提高了抗生素治疗的疗效,且没有任何明显的并发症。